Table 1.
Clinical and Epidemiologic Characteristics of Patients With PD.
| Total, N = 12 | Group A (ROT + Drug Therapy), n = 6 | Group B (Drug Therapy), n = 6 | P a | |
|---|---|---|---|---|
| Variablesb | ||||
| Genderc | 12 (100%) | 6 (50%) | 6 (50%) | |
| Female | 5 (41.67%) | 3 (50%) | 2 (33.33%) | 1 |
| Male | 7 (58.33%) | 3 (50%) | 4 (66.67%) | |
| Age | 72.08 ± 13.53 | 77 ± 9.34 | 67.16 ± 17.15 | .122 |
| Age at onset of symptoms | 59.75 ± 13.19 | 64.34 ± 8.14 | 57.85 ± 16.50 | .123 |
| Disease duration | 12 ± 5.78 | 12.33 ± 7.06 | 11.66 ± 4.84 | .426 |
| Hoehn and Yahr | 2.41 ± 1.35 | 2.75 ± 1.83 | 2.41 ± 1.46 | .367 |
| UPDRS–III | 23.75 ± 13.93 | 23 ± 16.23 | 24.5 ± 14.17 | .434 |
| Schooling | 6.41 ± 3.52 | 7 ± 4.39 | 5.83 ± 2.19 | .303 |
| Drug therapyc | 12 (100%) | 6 (50%) | 6 (50%) | |
| Rivastigmine (6 mg/d bid or 10 cm2 patch) | 6 (50%) | 3 (50%) | 3 (50%) | 1 |
| Donepezil (10 mg) | 6 (50%) | 3 (50%) | 3 (50%) | |
| First assessment | ||||
| Scopa-Cog | 11 ± 6.09 | 9.83 ± 5.78 | 12.16 ± 6.17 | .275 |
| CERAD | 69.41 ± 17.95 | 65.83 ± 19.40 | 73 ± 15.56 | .341 |
| CDT | 4.08 ± 2.84 | 3.16 ± 3.06 | 5 ± 2.82 | .153 |
Abbreviations: CDT, Clock Drawing Test; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; PD, Parkinson’s disease; ROT, reality orientation therapy; UPDRS, Unified Parkinson Disease Rating Scale.
aStatistically significant differences between groups A and B.
bAge, schooling, disease duration, and onset of symptoms are given in years. Student t test or Mann-Whitney test.
cFisher exact test.